Kamada (NASDAQ:KMDA) Downgraded by StockNews.com to Buy

Kamada (NASDAQ:KMDA) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Tuesday.

KMDA has been the subject of a number of other research reports. Benchmark assumed coverage on Kamada in a research report on Friday, March 21st. They issued a “buy” rating and a $15.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Kamada in a research note on Thursday, March 6th.

Kamada Stock Down 2.5 %

Shares of KMDA opened at $6.90 on Tuesday. The company has a 50 day moving average of $7.18 and a two-hundred day moving average of $6.29. Kamada has a twelve month low of $4.74 and a twelve month high of $9.16. The company has a market cap of $396.61 million, a price-to-earnings ratio of 24.64, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97.

Hedge Funds Weigh In On Kamada

Several hedge funds have recently made changes to their positions in KMDA. Aristides Capital LLC grew its stake in Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock valued at $387,000 after purchasing an additional 6,850 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 1,549 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of Kamada by 54.2% during the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 8,260 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in Kamada in the third quarter valued at approximately $77,000. Finally, JPMorgan Chase & Co. purchased a new position in Kamada during the 4th quarter worth approximately $67,000. 20.38% of the stock is owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.